Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

Blockbuster weight loss drugs like Ozempic, Wegovy and Mounjaro may slash the risk of a disorder affecting nearly 7million ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...

Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in weight loss. These medications belong to a class of drugs known as GLP-1 ...

Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone ...